Health Care & Life Sciences » Pharmaceuticals | GRUPO International Inc.

GRUPO International Inc. | Income Statement

Fiscal year is October-September. All values USD Thousands.
2006
2007
2008
2009
2010
Cost of Goods Sold (COGS) incl. D&A
16.30
16.10
54.60
0.50
0.50
Gross Income
16.30
16.10
54.60
0.50
0.50
SG&A Expense
127.20
39.30
41.10
42.80
55.10
Unusual Expense
-
-
566.00
-
-
Pretax Income
143.50
153.90
445.80
43.40
55.60
Consolidated Net Income
143.50
153.90
445.80
43.40
55.60
Net Income
143.50
153.90
445.80
43.40
55.60
Net Income After Extraordinaries
143.50
153.90
445.80
43.40
55.60
Net Income Available to Common
143.50
153.90
445.80
43.40
55.60
EPS (Basic)
0.01
0.02
0.05
-
0.01
Basic Shares Outstanding
9,830.70
9,830.70
9,830.70
9,830.70
9,980.20
EPS (Diluted)
0.01
0.02
0.05
0.00
0.01
Diluted Shares Outstanding
9,830.70
9,830.70
9,830.70
9,830.70
9,980.20
EBITDA
127.20
137.70
65.60
42.80
55.10
Other Operating Expense
-
98.40
24.50
-
-

About GRUPO International

View Profile
Address
14 Laurel Boulevard
Collingwood Ontario L9Y 5A8
Canada
Employees -
Website -
Updated 07/08/2019
Grupo International, Inc. operates as a development stage company, which is engaged in development and marketing of a proposed vaccine designed to combat HIV/AIDS. The company operates through two distinct divisions: The Pharmaceutical Division and The Basic Materials Division. The Pharmaceutical division will continually look for medical cures.